Neuropsychological and central neurologic effects of cancer immunotherapy: the start of a new challenge.
Saved in:
| Title: | Neuropsychological and central neurologic effects of cancer immunotherapy: the start of a new challenge. |
|---|---|
| Authors: | Joly, Florence (AUTHOR), Castel, Hélène (AUTHOR), Compter, Annette (AUTHOR), Nicola, Celeste (AUTHOR), Duivon, Mylène (AUTHOR), Lange, Marie (AUTHOR) |
| Source: | Journal of Clinical & Experimental Neuropsychology. Oct2025, Vol. 47 Issue 8, p768-787. 20p. |
| Subjects: | Immunotherapy, Cognition disorders, Quality of life, Chimeric antigen receptors, Psychological factors, Immune checkpoint inhibitors, Neuroinflammation |
| Abstract: | Introduction: Cognitive difficulties are frequently reported after cancer treatments, such as chemotherapy or hormone therapy, and have a negative impact on patients' quality of life. Recently, some studies have shown that new cancer treatments, such as immunotherapy agents, can induce cognitive changes. Method: This review presents the central neurological immune adverse events of immunotherapy treatments including Immune Checkpoint Inhibitors (ICI) and Chimeric Antigen Receptor (CAR) T-cell therapy. The physiopathological mechanisms and risk factors are developed and clinical studies on immunotherapy agents and cognition (among adult patients, using validated questionnaires and/or cognitive tests), psychological factors and quality of life were presented. Results: Neurological toxicities are frequently observed with CAR-T cell therapies at acute stage, such as the immune effector cell-associated neurotoxicity syndrome (ICANS), inducing cognitive disorders such as disorientation and aphasia. However, few studies have accurately assessed the impact of immunotherapy on cognition. The methodology of these studies is heterogeneous and they mainly included nonspecific self-report questionnaires of cognitive complaints. Variable results have been obtained concerning the cognitive impact of ICI and CAR-T cell several months following immunotherapy: overall, while some studies reported cognitive difficulties (mainly processing speed and executive functions), the majority has not. Although anxiety and depression are frequently reported in patients treated with ICI or CAR-T cells, these symptoms tend to decrease after the start of immunotherapy. The current neurobiological investigations are too fragmentary to explain neurological symptoms and potential cognitive alteration, but neuroinflammation, vascular inflammation, brain blood barrier disruption, and immune cell brain infiltration would constitute common mechanisms relayed by CAR-T and to a lesser degree, ICI. Conclusions: Acute neurological toxicities following CAR-T cell therapies are a major issue. Further studies are needed to better assess cognitive difficulties after the initiation of immunotherapy, in particular ICI, to better understand the physiopathology, including imaging studies, and risk factors. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Clinical & Experimental Neuropsychology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 190207567 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Neuropsychological and central neurologic effects of cancer immunotherapy: the start of a new challenge. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Joly%2C+Florence%22">Joly, Florence</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Castel%2C+Hélène%22">Castel, Hélène</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Compter%2C+Annette%22">Compter, Annette</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nicola%2C+Celeste%22">Nicola, Celeste</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Duivon%2C+Mylène%22">Duivon, Mylène</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lange%2C+Marie%22">Lange, Marie</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Journal+of+Clinical+%26+Experimental+Neuropsychology%22">Journal of Clinical & Experimental Neuropsychology</searchLink>. Oct2025, Vol. 47 Issue 8, p768-787. 20p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Immunotherapy%22">Immunotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Cognition+disorders%22">Cognition disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Quality+of+life%22">Quality of life</searchLink><br /><searchLink fieldCode="DE" term="%22Chimeric+antigen+receptors%22">Chimeric antigen receptors</searchLink><br /><searchLink fieldCode="DE" term="%22Psychological+factors%22">Psychological factors</searchLink><br /><searchLink fieldCode="DE" term="%22Immune+checkpoint+inhibitors%22">Immune checkpoint inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Neuroinflammation%22">Neuroinflammation</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Introduction: Cognitive difficulties are frequently reported after cancer treatments, such as chemotherapy or hormone therapy, and have a negative impact on patients' quality of life. Recently, some studies have shown that new cancer treatments, such as immunotherapy agents, can induce cognitive changes. Method: This review presents the central neurological immune adverse events of immunotherapy treatments including Immune Checkpoint Inhibitors (ICI) and Chimeric Antigen Receptor (CAR) T-cell therapy. The physiopathological mechanisms and risk factors are developed and clinical studies on immunotherapy agents and cognition (among adult patients, using validated questionnaires and/or cognitive tests), psychological factors and quality of life were presented. Results: Neurological toxicities are frequently observed with CAR-T cell therapies at acute stage, such as the immune effector cell-associated neurotoxicity syndrome (ICANS), inducing cognitive disorders such as disorientation and aphasia. However, few studies have accurately assessed the impact of immunotherapy on cognition. The methodology of these studies is heterogeneous and they mainly included nonspecific self-report questionnaires of cognitive complaints. Variable results have been obtained concerning the cognitive impact of ICI and CAR-T cell several months following immunotherapy: overall, while some studies reported cognitive difficulties (mainly processing speed and executive functions), the majority has not. Although anxiety and depression are frequently reported in patients treated with ICI or CAR-T cells, these symptoms tend to decrease after the start of immunotherapy. The current neurobiological investigations are too fragmentary to explain neurological symptoms and potential cognitive alteration, but neuroinflammation, vascular inflammation, brain blood barrier disruption, and immune cell brain infiltration would constitute common mechanisms relayed by CAR-T and to a lesser degree, ICI. Conclusions: Acute neurological toxicities following CAR-T cell therapies are a major issue. Further studies are needed to better assess cognitive difficulties after the initiation of immunotherapy, in particular ICI, to better understand the physiopathology, including imaging studies, and risk factors. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Journal of Clinical & Experimental Neuropsychology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=190207567 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/13803395.2025.2498713 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 20 StartPage: 768 Subjects: – SubjectFull: Immunotherapy Type: general – SubjectFull: Cognition disorders Type: general – SubjectFull: Quality of life Type: general – SubjectFull: Chimeric antigen receptors Type: general – SubjectFull: Psychological factors Type: general – SubjectFull: Immune checkpoint inhibitors Type: general – SubjectFull: Neuroinflammation Type: general Titles: – TitleFull: Neuropsychological and central neurologic effects of cancer immunotherapy: the start of a new challenge. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Joly, Florence – PersonEntity: Name: NameFull: Castel, Hélène – PersonEntity: Name: NameFull: Compter, Annette – PersonEntity: Name: NameFull: Nicola, Celeste – PersonEntity: Name: NameFull: Duivon, Mylène – PersonEntity: Name: NameFull: Lange, Marie IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: Oct2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 13803395 Numbering: – Type: volume Value: 47 – Type: issue Value: 8 Titles: – TitleFull: Journal of Clinical & Experimental Neuropsychology Type: main |
| ResultId | 1 |
